? 關(guān)鍵詞 糖尿病?胰島素?阿米替林 艾美賽珠單抗 遺傳性血色病蛋白 哌喹 CAR-T細胞 武利尤單抗 特瑞普利單抗?MASP-2抗體? ?

#今日行業(yè)熱點#

①The Lancet：Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial 臨床試驗：在成人1型糖尿病患者中胰島素周制劑icodec胰島素與超長效胰島素類似物德谷胰島素的一項3a期、隨機、開放標簽、達標試驗 DOI: 10.1016/S0140-6736(23)02179-7 ②The Lancet：Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial 臨床試驗：三環(huán)類抗抑郁藥阿米替林低劑量和滴定用于腸易激綜合征(IBS)的隨機、雙盲、安慰劑對照試驗 DOI: 10.1016/S0140-6736(23)01523-4 ③The Lancet Haematology：Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study 臨床分析：雙特異性抗體艾美賽珠單抗（Emicizumab）用于預防獲得性血友病A患者出血的一項開放標簽、單組、2期臨床試驗的最終結(jié)果 DOI: 10.1016/S2352-3026(23)00280-6 ④The Lancet Gastroenterology and Hepatology：MST4 kinase regulates immune thrombocytopenia by phosphorylating STAT1-mediated M1 polarization of macrophages 臨床分析：鐵調(diào)素的肽模擬物Rusfertide用于遺傳性血色病蛋白(HFE)相關(guān)血色病的開放標簽、多中心、概念驗證的Ⅱ期試驗 DOI: 10.1016/S2468-1253(23)00250-9 ⑤The Lancet Infectious Diseases：Impact of piperaquine resistance in Plasmodium falciparum on malaria treatment effectiveness in French Guiana: a descriptive epidemiological study 描述性流行病學研究：惡性瘧原蟲(Plasmodium falciparum)中哌喹耐藥性對瘧疾治療效果的影響 DOI: 10.1016/S1473-3099(23)00502-9 ⑥The Lancet Oncology：Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study 序貫導向CD19和導向CD22的嵌合抗原受體(CAR)T細胞用于兒童難治性或復發(fā)性急性B淋巴細胞白血病的單組、Ⅱ期研究 DOI: 10.1016/S1470-2045(23)00436-9 ⑦武利尤單抗（Nivolumab）單藥輔助用于IIB或IIC期黑色素瘤12歲以上及成人患者的補充生物制劑許可申請（sBLA）獲FDA許可 ⑧PD-1抑制劑特瑞普利單抗用于晚期腎癌（RCC）患者的關(guān)鍵Ⅲ期臨床（RENOTORCH）及用于結(jié)外NK/T細胞淋巴瘤（ENKTL）的Ⅱ期臨床積極結(jié)果將于ESMO2023大會上公布 ⑨新型大環(huán)肽類C5補體抑制劑Zilucoplan獲FDA批準上市，用于抗乙酰膽堿受體（AChR）抗體陽性的全身型重癥肌無力（gMG） ⑩MASP-2抗體Marsoplimab治療IgA腎病的Ⅲ期臨床的中期分析結(jié)果未達到主要研究終點，將終止ARTEMIS-IGAN 臨床試驗 科學探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！